Deferasirox
Back to searchMolecule Structure
Scientific Name
Deferasirox
Description of the Drug
Deferasirox is an iron chelator used to treat chronic iron overload caused by blood transfusions. Also used in patients with non-transfusion-dependent thalassemia syndromes, and in patients with elevated liver iron concentration and serum ferritin.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB01609
http://www.drugbank.ca/drugs/DB01609
Brand Name(s)
Deferasirox, Exjade, Jadenu, Jadenu sprinkle
Company Owner(s)
Teva Pharmaceuticals Usa Inc, Alkem Laboratories Ltd, Msn Laboratories Private Ltd, Cipla Ltd, Alembic Pharmaceuticals Ltd, Piramal Healthcare Uk Ltd, Celltrion Inc, Sun Pharmaceutical Industries Ltd, Actavis Elizabeth Llc, Bionpharma Inc
Mechanism(s) Of Action
Target Name | Target Type | Action Type | Target ChEMBL ID |
---|---|---|---|
Iron | METAL | CHELATING AGENT | CHEMBL2363058 |
Clinical Trial(s)
Unichem Links
SureChEMBL | SCHEMBL61756 | ||
Human Metabolome Database | HMDB0015547 | ||
DrugBank | DB01609 | ||
PubChem: Thomson Pharma | 14853198 | ||
PubChem | 214348 | ||
LINCS | LSM-45297 | ||
Nikkaji | J1.213.542D | ||
PDBe | JBL | ||
BindingDB | 50088376 | ||
EPA CompTox Dashboard | DTXSID1048596 | ||
DrugCentral | 3128 | ||
rxnorm | EXJADE | JADENU | DEFERASIROX |
PubChem: Drugs of the Future | 12015358 | ||
ChEBI | 49005 | ||
ZINC | ZINC000001481815 |